Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

97.24 +1.95 (+2.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,434,651
Open 95.57
Bid (Size) 94.82 (1)
Ask (Size) 99.87 (1)
Prev. Close 95.29
Today's Range 95.56 - 97.69
52wk Range 70.73 - 117.77
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier. 
Via Investor's Business Daily
3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize
The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story. 
Via The Motley Fool

Performance

YTD
-3.35%
-3.35%
1 Month
-3.71%
-3.71%
3 Month
-6.04%
-6.04%
6 Month
+14.71%
+14.71%
1 Year
+26.12%
+26.12%

More News

Read More
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
Via Benzinga
Preview: Biomarin Pharmaceutical's Earnings
Via Benzinga
Analyst Ratings for Biomarin Pharmaceutical
Via Benzinga
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
Via MarketBeat
Exposures Product Safety
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
Via Benzinga
Why BioMarin Shares Are Plunging Today?
Via Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
Via Investor's Business Daily
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
Via Investor's Business Daily
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
uniQure Stock Trying To Close In On Key Technical Measure
Via Investor's Business Daily
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga
3 Prime Healthcare Takeover Targets
Via The Motley Fool
Moderna Stock Getting Closer To Key Technical Benchmark
Via Investor's Business Daily
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
Via InvestorPlace
Cramer Is Holding This Biotech Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.